An observational study in Degenerative Joint Disease and Control Subjects, sponsored by University of Minnesota. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by University of Minnesota · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Joint Diseases with a site in United States — 15 open to participants now, 27 under way, 5 of them phase 3. Joint Diseases · United States.
Among the 149 studies in Joint Diseases with a site in United States, this one is the 23rd largest by planned enrollment of the 30 observational ones that give a count, is one of 4 that started in 2025, is one of 31 observational ones, reaches primary completion later than 13 of the 26 other live ones, and was the 143rd registered.
386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.
Browse Joint Diseases studies →15 of the 149 studies in Joint Diseases with a site in United States are open now. Recruiting first, the newest first:
Restor3D · Sites in United States
Ages 18+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+
North Texas Medical Research Institute, PLLC · Sites in United States
Ages 30–85
Shirley Ryan AbilityLab · Sites in United States
Ages 50–75
Emory University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 21 · Phase 3 26 · Phase 4 11
First in 1991; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 86 across 116 observational studies indexed under Joint Diseases.
Median enrollment 163 across the 118 interventional studies, 115 across the 30 observational. Of the 111 that completed or were terminated, 60 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 149 have an industry lead sponsor. The 10 most frequent:
University of Minnesota is the lead sponsor of 1,219 studies on the registry; 199 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
University of Minnesota has 1 study filed under Joint Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Joint Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550024CrannMedSakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | 2026-12 |
| NCT07553273The University of Texas Medical Branch, GalvestonVibratory Anesthesia on Pain Following Corticosteroid Injections | 2027-04 |
| NCT07008690University of MinnesotaMRI of the TMJ in Patients With DJD | 2027-05-31 |
| NCT02351414MicroPort Orthopedics Inc.Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts | 2027-06 |
| NCT05292339Emory UniversityKetorolac in Upper Extremity Tendinopathy and Arthropathy | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 149 studies in Joint Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational research is comparative in design, that is assessing the change in qMRI measures in degenerative changes of the TMJ in patients diagnosed with DJD. These patients will be imaged multiple times over the course of 18 months, using clinical 3T MRI scanners located at the Center for Magnetic Resonance Research (CMRR), and their findings will be compared to controls; individuals who are not diagnosed with DJD. No investigational agents or MRI contrast agents will be used.
Participants with DJD will be recruited during routine examinations at the TMD clinic located at the School of Dentistry, UMN. They will be approached by their clinicians for potential enrollment in an MRI study. Eligibility will be assessed based on prior imaging and medical history. If eligible and interested, participants will complete a consent process and a CMRR questionnaire which is a safety screening questionnaire, followed by scheduling for a 2-hour MRI session at the CMRR. During the visit, participants will undergo approximately 90 minutes of qMRI scans using a 15-channel face coil. Afterward, they'll complete an exit questionnaire. Additional follow-up scans may occur over 18 months, following the same procedures, while control participants will have two scans 1-4 weeks apart.
Participants with DJD will be recruited during routine examinations at the TMD clinic located at the School of Dentistry, UMN. If eligible and interested, participants will undergo approximately 90 minutes of qMRI scans. Additional follow-up scans may occur over 18 months, while control participants will have two scans 1-4 weeks apart.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To participate in this study, patients (with DJD) must:
To participate in this study, controls (participants without DJD) must:
Participants will be excluded if they:
to MRI. Exclusion criteria for MRI are:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants must be 18 years or older, who can attend a 2-hour MRI appointment at the CMRR. They must have a clinically confirmed diagnosis of degenerative joint disease (DJD) based on CT, radiographs, or traditional MRI.
Diagnostic Test: MRI
Participants must be 18 years or older who can attend a 2-hour MRI appointment at the CMRR. They must confirm the absence of any pre-existing temporomandibular joint (TMJ) disease.
Diagnostic Test: Magnetic Resonance Imaging
This exploratory study will longitudinally image patients diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 18 months using 3T MRI.
For comparison, this exploratory study will image patients that are not diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 4 weeks.
Assess the change in qMRI measures in degenerative changes of the TMJ over time
We will assess these changes between baseline MRI and multiple MRI scanning session over the course of 18 months. We will group patients who do (case group) and do not (control group) have clinical progression of DJD based on their existing CT scans and/or radiograph imaging acquired by their clinician to confirm their diagnosis. These findings will be evaluated through subjective observations and the ability to identify various anatomical structures. Additionally, intra- and inter-rater reliability analyses will be conducted to assess the consistency of the MRI interpretations
Time frame: 1.5 year
Build a rich MRI data set
This exploratory study is designed to provide useful data regardless of the outcomes. This study will begin to build a rich MRI data set that will lay the groundwork for future, larger studies to more fully evaluate the quantitative MRI techniques and address important clinical questions.
Time frame: 1.5 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.
Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.